Liothyronine

(asked on 23rd July 2018) - View Source

Question to the Department of Health and Social Care:

To ask Her Majesty's Government whether they intend to review local and regional guidance by NHS bodies which do not follow current national guidance in relation to the prescribing of liothyronine (T3).


Answered by
Lord O'Shaughnessy Portrait
Lord O'Shaughnessy
This question was answered on 25th July 2018

We have no intention to review guidance by National Health Service bodies. However, we are informed by NHS England that the joint clinical working group has agreed that NHS clinical commissioners will reiterate to clinical commissioning groups (CCGs) by the end of July 2018 that the intention of the guidance published last November was to end the routine prescription of liothyronine only where it was clinically appropriate to do so.

CCGs are accountable to NHS England, which has a key role to ensure that they, as statutory organisations, deliver the best possible services and outcomes for patients within their financial allocation. Where there are concerns about CCGs failing or at risk of failing to discharge its functions, NHS England has the ability to exercise formal powers to either provide enhanced support to a CCG, or in rare circumstances to intervene. Although the Department ultimately holds NHS England to account for its commissioning activity, including that of CCGs, the Health and Social Care Act 2012 ensures commissioning activity meets the requirements of each local area.

Reticulating Splines